Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CONCETTA M FORCHETTI

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1184656852
CMS profile
189389
Location
ELK GROVE VILLAGE, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$15,350.00

6 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $15,350.00 6

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
EISAI INC. $12,285.00 5
Biogen, Inc. $3,065.00 1

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CONCETTA M FORCHETTI

NPI 1184656852 · CMS profile ID 189389

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

ELK GROVE VILLAGE, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1184656852?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CONCETTA M FORCHETTI, NPI 1184656852, CMS profile ID 189389. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1184656852?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). CONCETTA M FORCHETTI, NPI 1184656852, CMS profile ID 189389. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1184656852?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
CONCETTA M FORCHETTI, NPI 1184656852, CMS profile ID 189389, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1184656852?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

6 matching records · $15,350.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 6 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–6 of 6.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
EISAI INC. $2,700.0012/21/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 926013089 CMS
EISAI INC. $810.0009/30/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 926013095 CMS
EISAI INC. $2,700.0007/30/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 926014845 CMS
EISAI INC. $4,995.0005/06/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 926013093 CMS
EISAI INC. $1,080.0005/05/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 926013091 CMS
Biogen, Inc. $3,065.0004/07/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923389415 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $8,113.42 4
PY2020 $565.00 1
PY2021 $38,624.37 33
PY2022 $15,350.00 6
PY2023 $16,660.79 32
PY2024 $39,378.02 40
PY2025 $50,287.88 49

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $908,463.90 81
PY2024 Principal investigator $630,831.36 79
PY2023 Recipient $591.95 2
PY2023 Principal investigator $1,785,779.63 92
PY2022 Recipient $10,066.00 2
PY2022 Principal investigator $1,648,640.76 51
PY2021 Recipient $1,310.44 2
PY2021 Principal investigator $1,377,364.84 65
PY2020 Recipient $2,195.35 2
PY2020 Principal investigator $1,008,121.30 81
PY2019 Recipient $294.51 1
PY2019 Principal investigator $1,007,212.44 33

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

79 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 GlaxoSmithKline, LLC. $5,244.00 12/19/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1156002347
Principal investigator 1 GlaxoSmithKline, LLC. $5,244.00 12/19/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1156002785
Principal investigator 1 Janssen Research & Development, LLC $14,154.00 12/19/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1079001496
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 12/16/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1079001472
Principal investigator 1 GlaxoSmithKline, LLC. $50.00 12/08/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1156001763
Principal investigator 1 GlaxoSmithKline, LLC. $100.00 12/08/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1156002889
Principal investigator 1 GlaxoSmithKline, LLC. $60.00 12/08/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1156003035
Principal investigator 1 GlaxoSmithKline, LLC. $9,858.72 12/08/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1156003151
Principal investigator 1 GlaxoSmithKline, LLC. $50.00 12/08/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1156003367
Principal investigator 1 Eli Lilly and Company $25,073.15 12/02/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A RANDOMIZED, DOUBLE-BLINDED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MEVIDALEN IN PATIENTS WITH ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1137352136
Principal investigator 1 Eli Lilly and Company $2,603.10 11/21/2024 Non-covered Recipient Entity
YALE UNIVERSITY
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1137370810
Principal investigator 1 GlaxoSmithKline, LLC. $50.00 11/20/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127525236
Principal investigator 1 GlaxoSmithKline, LLC. $50.00 11/20/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127525238
Principal investigator 1 GlaxoSmithKline, LLC. $120.00 11/20/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127532686
Principal investigator 1 Janssen Research & Development, LLC $15,450.00 11/18/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1079001440
Principal investigator 1 GlaxoSmithKline, LLC. $16,511.70 11/15/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127525244
Principal investigator 1 Janssen Research & Development, LLC $180.00 11/11/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1079001488
Principal investigator 1 Janssen Research & Development, LLC $339.00 11/07/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1079001474
Principal investigator 1 Janssen Research & Development, LLC $114.00 11/07/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1079001492
Principal investigator 1 Janssen Research & Development, LLC $600.00 10/23/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1079001482
Principal investigator 1 GlaxoSmithKline, LLC. $100.00 10/22/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127532574
Principal investigator 1 GlaxoSmithKline, LLC. $9,635.16 10/17/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127525240
Principal investigator 1 GlaxoSmithKline, LLC. $55.20 10/17/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127525248
Principal investigator 1 GlaxoSmithKline, LLC. $1,250.00 10/17/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127532642
Principal investigator 1 GlaxoSmithKline, LLC. $120.00 10/17/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127532646
Principal investigator 1 GlaxoSmithKline, LLC. $5,244.00 10/17/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127532676
Principal investigator 1 GlaxoSmithKline, LLC. $1,080.00 10/17/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127532678
Principal investigator 1 GlaxoSmithKline, LLC. $5,244.00 10/17/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127532680
Principal investigator 1 Janssen Research & Development, LLC $7,016.00 10/04/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1079001450
Principal investigator 1 GlaxoSmithKline, LLC. $8,462.16 09/25/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127525246
Principal investigator 1 GlaxoSmithKline, LLC. $4,231.08 09/25/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127532576
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $55,284.00 09/05/2024 Non-covered Recipient Entity
Alexian Brothers Health System
Phase 2 PoC in Early AD Patients - A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimer s Disease (TargetT No dispute reported 06/30/2026 1123475770
Principal investigator 1 Janssen Research & Development, LLC $1,020.00 09/02/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1079001476
Principal investigator 1 Janssen Research & Development, LLC $1,020.00 09/02/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1079001480
Principal investigator 1 Janssen Research & Development, LLC $9,714.00 08/29/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1079001448
Principal investigator 1 Janssen Research & Development, LLC $680.00 08/15/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1079001454
Principal investigator 1 Janssen Research & Development, LLC $340.00 08/15/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1079001490
Principal investigator 1 Janssen Research & Development, LLC $340.00 08/12/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1079001438
Principal investigator 1 Janssen Research & Development, LLC $340.00 08/12/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1079001444
Principal investigator 1 Janssen Research & Development, LLC $340.00 08/12/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1079001468
Principal investigator 1 Eli Lilly and Company $2,802.01 08/05/2024 Non-covered Recipient Entity
YALE UNIVERSITY
A RANDOMIZED, DOUBLE-BLINDED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MEVIDALEN IN PATIENTS WITH ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1137370812
Principal investigator 1 Janssen Research & Development, LLC $4,007.00 08/01/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1079001478
Principal investigator 1 GlaxoSmithKline, LLC. $5,244.00 07/18/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127525250
Principal investigator 1 Janssen Research & Development, LLC $1,104.00 07/11/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1079001456
Principal investigator 1 Janssen Research & Development, LLC $4,158.00 07/04/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1079001484
Principal investigator 1 GlaxoSmithKline, LLC. $19,009.50 06/25/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127532674
Principal investigator 1 Janssen Research & Development, LLC $600.00 06/14/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1079001458
Principal investigator 1 Janssen Research & Development, LLC $12,811.00 05/31/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1079001464
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $6,256.48 05/28/2024 Non-covered Recipient Entity
Alexian Brothers Neurosciences Institute Clinical Research
Phase 2 PoC in Early AD Patients - A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimer s Disease (TargetT No dispute reported 06/30/2026 1123475772
Principal investigator 1 GlaxoSmithKline, LLC. $12,617.34 05/21/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127532684
Principal investigator 1 GlaxoSmithKline, LLC. $4,231.08 05/21/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127532688
Principal investigator 1 Janssen Research & Development, LLC $600.00 05/20/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1079001470
Principal investigator 1 Janssen Research & Development, LLC $14,926.00 04/29/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1079001452
Principal investigator 1 Eli Lilly and Company $1,139.73 04/25/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 1137352134
Principal investigator 1 Janssen Research & Development, LLC $90.00 04/12/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1079001446
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 04/12/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1079001460
Principal investigator 1 Janssen Research & Development, LLC $310.00 04/12/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1079001462
Principal investigator 1 Janssen Research & Development, LLC $90.00 04/12/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1079001466
Principal investigator 1 Janssen Research & Development, LLC $205.00 04/12/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1079001486
Principal investigator 1 Janssen Research & Development, LLC $90.00 04/12/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1079001498
Principal investigator 1 Janssen Research & Development, LLC $13,567.00 04/01/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1079001442
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $9,460.92 03/29/2024 Non-covered Recipient Entity
Advarra Dba Schulman Associates Irb
Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease (TargetTau-1) No dispute reported 06/30/2026 1123475099
Principal investigator 1 Eli Lilly and Company $2,586.15 03/08/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1137353754
Principal investigator 1 Janssen Research & Development, LLC $2,724.00 03/08/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1079001502
Principal investigator 1 Janssen Research & Development, LLC $4,603.00 03/04/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1079001500
Principal investigator 1 GlaxoSmithKline, LLC. $750.00 02/26/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127525242
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 02/26/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127532572
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 02/26/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127532578
Principal investigator 1 GlaxoSmithKline, LLC. $10,000.00 02/26/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127532644
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 02/26/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1127532682
Principal investigator 1 Janssen Research & Development, LLC $4,846.00 02/08/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 1079001494
Principal investigator 1 Eli Lilly and Company $45.32 01/25/2024 Non-covered Recipient Entity
YALE UNIVERSITY
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1137370654
Principal investigator 1 Biogen, Inc. $30,860.00 01/09/2024 Non-covered Recipient Entity
Alexian Brothers Health System
Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimers disease Who Had Previously Participated in the Aducanumab Studies221AD103, 221AD301, 221AD302 and 221AD205 No dispute reported 06/30/2026 1104838976
Principal investigator 1 Eli Lilly and Company $34,003.00 01/09/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1137353150
Principal investigator 1 Genentech, Inc. $52,409.56 01/09/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
Phase II study for Moderate AD No dispute reported 06/30/2026 1133378938
Principal investigator 1 Genentech, Inc. $2,099.00 01/09/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
Phase II study for Moderate AD No dispute reported 06/30/2026 1133378940
Principal investigator 1 Genentech, Inc. $948.00 01/09/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
Phase II study for Moderate AD No dispute reported 06/30/2026 1133378942
Principal investigator 1 Eli Lilly and Company $83,690.00 01/02/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 1137353056
Principal investigator 1 Eli Lilly and Company $72,481.00 01/02/2024 Non-covered Recipient Entity
ALEXIAN BROTHERS HEALTH SYSTEM
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1137353478